AGENUS INC — Director's Dealing 2020

May 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2020-05-12

Reporting Person: ARMEN GARO H (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-12	Common Stock	J	159000	$2.56	Acquired	1051155	Direct
2020-05-14	Common Stock	J	159000	$2.29	Disposed	892155	Direct
2020-05-14	Common Stock	J	600000	$2.29	Disposed	292155	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	125969	Indirect
Common Stock	863046	Indirect

Footnotes

F1: Represents a distribution from the Garo Armen 2018 2 Year AG GRAT.

F2: Represents deposit into the Garo Armen 2018 2 Year AG GRAT.

F3: Represents deposit into the Garo Armen 2020 2 Year AG GRAT.

F4: Shares are held in Dr. Armen's IRA accounts.

F5: Dr. Armen is trustee and has investment authority for the Garo Armen 2018 2 Year AG GRAT holder of 159,000 shares of our Common Stock and for the Garo Armen 2020 2 Year AG GRAT holder of 600,000 shares of our Common Stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.